Biomarkers to Predict Cancer Therapy-related Cardiotoxicity
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorMayo Clinic
About this trial
This study evaluates why some cancer patients but not others experience changes in heart function following treatment with chemotherapy.
Eligibility criteria
Qualifiers
18 years of age or older
Treated for any malignancy with any type of chemotherapy including oral, parenteral therapy and immunotherapy
Diagnosed with cardiotoxicity defined as; cardiomyopathy, symptomatic heart failure, asymptomatic reduced systolic function, acute coronary syndrome, myocardial infarction, critical limb ischemia, cardiac arrhythmias or myocarditis possibly related to prior cancer treatment
Completed chemotherapy with no cardiotoxicity at least two years post treatment
Disqualifiers
None
Trial design
Treatments tested in this trial
- Non-Interventional Study
Treatment groups
693 Participants
are divided into 1 treatment groupSponsors and collaborators
Mayo Clinic
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
Collaborator
Source ClinicalTrials.gov